228 related articles for article (PubMed ID: 35207255)
21. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
[TBL] [Abstract][Full Text] [Related]
22. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
[TBL] [Abstract][Full Text] [Related]
23. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
Gouni-Berthold I
J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
[TBL] [Abstract][Full Text] [Related]
24. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM
Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
[TBL] [Abstract][Full Text] [Related]
25. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
[TBL] [Abstract][Full Text] [Related]
26. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
27. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
[TBL] [Abstract][Full Text] [Related]
28. [Familial chylomicronemia].
Quiroga-Padilla PJ; Gaete PV; Mendivil CO
Medicina (B Aires); 2020; 80(4):348-358. PubMed ID: 32841138
[TBL] [Abstract][Full Text] [Related]
29. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
31. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
32. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
Paquette M; Amyot J; Fantino M; Baass A; Bernard S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and Disposition of Volanesorsen, a 2'-
Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
[TBL] [Abstract][Full Text] [Related]
34. A 3-day-old neonate with severe hypertriglyceridemia from novel mutations of the GPIHBP1 gene.
Buonuomo PS; Bartuli A; Rabacchi C; Bertolini S; Calandra S
J Clin Lipidol; 2015; 9(2):265-70. PubMed ID: 25911085
[TBL] [Abstract][Full Text] [Related]
35. Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome.
Larouche M; Brisson D; Morissette MC; Gaudet D
Orphanet J Rare Dis; 2023 Jun; 18(1):167. PubMed ID: 37370069
[TBL] [Abstract][Full Text] [Related]
36. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
Baass A; Paquette M; Bernard S; Hegele RA
J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
Rabacchi C; Pisciotta L; Cefalù AB; Noto D; Fresa R; Tarugi P; Averna M; Bertolini S; Calandra S
Atherosclerosis; 2015 Jul; 241(1):79-86. PubMed ID: 25966443
[TBL] [Abstract][Full Text] [Related]
38. [Severe hypertriglyceridemia : Diagnostics and new treatment principles].
Kassner U; Dippel M; Steinhagen-Thiessen E
Internist (Berl); 2017 Aug; 58(8):866-876. PubMed ID: 28516251
[TBL] [Abstract][Full Text] [Related]
39. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome.
Rouis M; Dugi KA; Previato L; Patterson AP; Brunzell JD; Brewer HB; Santamarina-Fojo S
Arterioscler Thromb Vasc Biol; 1997 Jul; 17(7):1400-6. PubMed ID: 9261273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
